NRX Pharmaceuticals, Inc. Gain (Loss) on Extinguishment of Debt
NRX Pharmaceuticals, Inc. (NRXP) reported Gain (Loss) on Extinguishment of Debt of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-08-14
- NRX Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for the quarter ending 2026-06-30 was $0.00.
- NRX Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for the quarter ending 2026-03-31 was $0.00.
- NRX Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-06-30 was $0.00.
- NRX Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-03-31 was -$1.28M.
- NRX Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for fiscal 2025 was -$1.28M.
- NRX Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for fiscal 2024 was $0.00.
- NRX Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for fiscal 2021 was $121.00K, a 65.63% decline from fiscal 2020.
- NRX Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for fiscal 2020 was $352.07K.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 3 month as first filed | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 6 month as first filed | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 9 month as first filed | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | |||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | ||||||
| 2025-12-31 | -$1.28M 10-K · filed 2026-03-23 | ||||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.28M 10-Q · filed 2026-08-14 | |||||
| 2025-03-31 | -$1.28M 10-Q · filed 2026-05-15 | ||||||
| 2024-12-31 | $0.00 10-K · filed 2026-03-23 | ||||||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | ||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 derived: sum of 3 quarters · filed 2023-03-31 | $121.00K 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $121.00K 10-Q · filed 2022-11-14 | $120.81K 10-Q · filed 2021-11-15 | $121.00K derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $121.00K 10-Q · filed 2022-08-15 | $120.81K 10-Q · filed 2021-08-16 | $121.00K derived: sum of 3 quarters · filed 2022-08-15 | $121.00K derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | $121.00K 10-Q · filed 2022-05-16 | $0.00 10-Q · filed 2021-05-21 | $121.00K derived: sum of 2 quarters · filed 2022-05-16 | $121.00K derived: sum of 3 quarters · filed 2022-05-16 | $121.00K derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-14 | $0.00 derived: sum of 2 quarters · filed 2021-05-14 | $0.00 derived: sum of 3 quarters · filed 2021-05-14 | $352.07K 10-K/A · filed 2021-05-14 | |||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-16 | $0.00 derived: sum of 2 quarters · filed 2020-11-16 | $352.07K 10-Q · filed 2020-11-16 | $352.07K derived: sum of 4 quarters · filed 2021-05-21 | |||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-14 | $352.07K 10-Q · filed 2020-08-14 | $352.07K derived: sum of 3 quarters · filed 2021-05-21 | $352.07K derived: sum of 4 quarters · filed 2021-05-21 | |||
| 2020-03-31 | $352.07K 10-Q · filed 2021-05-21 | $352.07K derived: sum of 2 quarters · filed 2021-05-21 | $352.07K derived: sum of 3 quarters · filed 2021-05-21 | $352.07K derived: sum of 4 quarters · filed 2021-05-21 | |||
| 2019-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-14 | $0.00 derived: sum of 2 quarters · filed 2021-05-14 | $0.00 derived: sum of 3 quarters · filed 2021-05-14 | $0.00 10-K/A · filed 2021-05-14 | |||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-16 | $0.00 derived: sum of 2 quarters · filed 2020-11-16 | $0.00 10-Q · filed 2020-11-16 | ||||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-14 | $0.00 10-Q · filed 2020-08-14 | |||||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |